Last edition
News about "Cadila Pharma"
Cadila Pharmaceuticals Introduces Dlorfast-M Tablets to Treat Allergic Rhinitis and Urticaria
Allergic rhinitis and urticaria are chronic health conditions that affect millions of people globally. Cadila Pharmaceuticals has introduced Dlorfast-M as a dual-action therapy targeting two pathways of the allergic response—histamine and leukotriene—aiming to provide wider and more effective symptom management.
Cadila Pharma | 14/10/2025 | By Dineshwori
Cadila Pharma facility in Dholka passes US FDA audit
US FDA Inspector Vivin George conducted the facility’s audit from April 3 to 7
Cadila Pharma | 20/04/2023 | By Sudeep Soparkar | 1396
Ethiopian Ambassador and FDA Director General opens Cadila's formulation lab
A high-level delegation of the Ethiopian Food and Drug Administration visited Cadila’s plant and office
Cadila Pharma | 21/06/2022 | By Sudeep Soparkar | 352
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy